MARKET

REPL

REPL

Replimune Group
NASDAQ
8.72
-0.52
-5.63%
Opening 12:49 06/10 EDT
OPEN
9.03
PREV CLOSE
9.24
HIGH
9.12
LOW
8.53
VOLUME
1.07M
TURNOVER
--
52 WEEK HIGH
13.24
52 WEEK LOW
1.500
MARKET CAP
720.03M
P/E (TTM)
-2.5377
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at REPL last week (0601-0605)?
Weekly Report · 2d ago
Replimune: Modeling The Coin Flip Of FDA Approval
Seeking Alpha · 5d ago
Acting FDA head vows to block political interference, Endpoint News says
TipRanks · 6d ago
U.S. Earnings Preview: Before Market Open June 4
Dow Jones · 6d ago
Replimune Chief Commercial Officer Christopher Sarchi sells 12,000 shares for $110,880
PUBT · 6d ago
Replimune's Path to Profitability Grows More Uncertain With Each Delayed Milestone
Barchart · 06/03 16:02
Analysts Offer Insights on Healthcare Companies: Replimune Group (REPL), Eli Lilly & Co (LLY) and Relay Therapeutics (RLAY)
TipRanks · 06/03 12:30
FDA issues draft guidance to help accelerated cell, gene therapies for patients
TipRanks · 06/02 14:03
More
About REPL
Replimune Group, Inc. is a clinical-stage biotechnology company engaged in the development of novel oncolytic immunotherapies. Its proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform is designed to have a unique dual local and systemic activity consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor-derived antigens and altering of the tumor microenvironment to ignite a systemic response. Its lead product candidate, RP1, is a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF. Its lead indication for its lead product candidate, RP1, is the potential treatment of advanced melanoma. Its pipeline product candidates include RP2 and RP3. It has designed its RP2 product candidate to express an anti-CTLA-4 antibody-like protein intended to block the inhibition of the immune response.

Webull offers Replimune Group Inc stock information, including NASDAQ: REPL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, REPL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading REPL stock methods without spending real money on the virtual paper trading platform.